Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
New Data Evaluating ABRAXANE In Early-Stage Breast Cancer And In Combination With Novel Investigational Agents To Be Presented At SABCS
http://www.medicalnewstoday.com/articles/132696.php
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that multiple studies of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 31st Annual San Antonio Breast Cancer Symposium on December 10-14, 2008.
Roswell Park Receives Grant To Study Link Between Breast Cancer And Low Vitamin D Levels
http://www.medicalnewstoday.com/articles/132552.php
Roswell Park Cancer Institute is the recipient of a $199,998 award from The Breast Cancer Research Foundation to study the link between vitamin D and the occurrence of breast cancer in white and African-American women.
----------------------------------------------
** CANCER / ONCOLOGY News **
Guided Therapeutics, Inc. Submits First Module Of Premarket Approval Application For Painless Cervical Cancer Detection To FDA
http://www.medicalnewstoday.com/articles/132713.php
<a href="http://www.guidedinc.com/" target="_blank" rel="nofollow">Guided Therapeutics, Inc.</a> (GT) (Pink Sheets: GTHP) today announced it submitted the first of three modules of its Premarket Approval (PMA) application to the U.
New Way Of Viewing Cells Could Lead To Easier Routes For Drug Manufacture
http://www.medicalnewstoday.com/articles/132701.php
Research by a Michigan State University chemist could eventually lead to a quicker and easier way of developing protein-based drugs that are key to treating a number of diseases, including cancer, diabetes and hepatitis.
Alnylam Forms Collaboration With University Of California, San Francisco To Investigate Therapeutic Silencing Of Key Gene Implicated In Uveal Melanoma
http://www.medicalnewstoday.com/articles/132697.php
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has formed an exclusive collaboration with the University of California, San Francisco (UCSF) to evaluate the potential of an RNAi therapeutic targeting a heterotrimeric G protein alpha-subunit, known as G-alpha q or GNAQ, for the treatment of metastatic uveal melanoma.
New Data Evaluating ABRAXANE In Early-Stage Breast Cancer And In Combination With Novel Investigational Agents To Be Presented At SABCS
http://www.medicalnewstoday.com/articles/132696.php
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that multiple studies of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 31st Annual San Antonio Breast Cancer Symposium on December 10-14, 2008.
Data From Eight Clinical Trials Facilitated By The Multiple Myeloma Research Consortium (MMRC) Presented At The ASH Annual Meeting
http://www.medicalnewstoday.com/articles/132694.php
The Multiple Myeloma Research Consortium (MMRC) today announced that data from eight clinical trials in its portfolio as well as findings from the MMRC Multiple Myeloma Genomics Initiative were presented at the American Society of Hematology's (ASH) 50th Annual Meeting and Exposition held Dec.
Cancer pain - Orexo: Abstral Receives Marketing Approval In Germany
http://www.medicalnewstoday.com/articles/132688.php
Orexo (STO:ORX) confirms the announcement made by ProStrakan Group plc (LSE:PSK), Orexo's partner for Abstral® in Europe and North America, that it has received a Marketing Authorisation from the German regulatory authority, BfArM for Abstral (for breakthrough cancer pain).
Oncology Drug Iressa Better Than Chemotherapy In Some Patients, According To New Report From Cutting Edge Information
http://www.medicalnewstoday.com/articles/132678.php
Iressa's sales are poised to increase on positive clinical results suggesting that AstraZeneca's targeted lung cancer therapy performs better than standard chemotherapy in many patients, according to a new report, <a href="http://www.
Gene Mutation That Causes Eye Cancer Discovered By UBC Researchers
http://www.medicalnewstoday.com/articles/132664.php
A University of British Columbia geneticist has discovered a gene mutation that can cause the most common eye cancer - uveal melanoma.Catherine Van Raamsdonk, an assistant professor of medical genetics in the UBC Faculty of Medicine and a team of researchers, have discovered a genetic mutation in a gene called GNAQ that could be responsible for 45 per cent of the cases of uveal melanoma.
Expected Surge In Older Cancer Survivors As Baby Boomers Age
http://www.medicalnewstoday.com/articles/132654.php
The United States could be faced with a national health care crisis in the coming decades as the country's baby boomer population ages and a growing number of older adults find themselves diagnosed with and living longer with cancer.
Earlier Diagnosis Of Oral Cancers
http://www.medicalnewstoday.com/articles/132642.php
Worldwide, more than 500,000 new cases of cancer of the mouth are diagnosed each year. The majority of these cancers are found too late, causing many people to die within five years of finding out they have cancer.
Survival Stable For Common Cancers In England
http://www.medicalnewstoday.com/articles/132607.php
Figures released by the Office for National Statistics today show that survival continues to vary widely between different types of cancer. Over 96 per cent of men diagnosed in England in 2000-2004 with cancer of the testis survived five years, as did 81 per cent of women diagnosed with breast cancer.
Tiny Delivery System With A Big Impact On Cancer Cells - Nano Letters
http://www.medicalnewstoday.com/articles/132592.php
Researchers at Penn State University are reporting for the first time that nanoparticles 1/5,000 the diameter of a human hair encapsulating an experimental anticancer agent, kill human melanoma and drug-resistant breast cancer cells growing in laboratory cultures.
Neogenix Oncology To Begin First Clinical Trial For A New Generation Of Diagnostic Products
http://www.medicalnewstoday.com/articles/132559.php
Neogenix Oncology, Inc. (Neogenix) announced today that the Institutional Review Board (IRB) at Conemaugh Valley Memorial Hospital (Memorial Medical Center) in Johnstown, Pennsylvania, has approved the company's protocol for its first Diagnostic Clinical Trial.
American Cancer Society Launches Quitline Program In India
http://www.medicalnewstoday.com/articles/132557.php
The American Cancer Society today announced that it is launching its Quitline® service in India. The program will be provided through multi-national employers with operations in India. The Society's Quitline program is a clinically proven, free telephone-based counseling service that provides counseling and pharmacological service to more than 100 employers and health plans and 13 states in the U.
Parents' Reactions To Child Cancer Determined By Type
http://www.medicalnewstoday.com/articles/132555.php
The type of cancer a child has goes a long way towards determining how his or her parents cope with the situation, according to a study from Karolinska Institutet. Parents of children treated for skeletal and brain tumours run a relatively much higher risk of becoming distressed and depressed than parents of children with other common types of cancer.
Roswell Park Receives Grant To Study Link Between Breast Cancer And Low Vitamin D Levels
http://www.medicalnewstoday.com/articles/132552.php
Roswell Park Cancer Institute is the recipient of a $199,998 award from The Breast Cancer Research Foundation to study the link between vitamin D and the occurrence of breast cancer in white and African-American women.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
Guided Therapeutics, Inc. Submits First Module Of Premarket Approval Application For Painless Cervical Cancer Detection To FDA
http://www.medicalnewstoday.com/articles/132713.php
<a href="http://www.guidedinc.com/" target="_blank" rel="nofollow">Guided Therapeutics, Inc.</a> (GT) (Pink Sheets: GTHP) today announced it submitted the first of three modules of its Premarket Approval (PMA) application to the U.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
No news for this category today.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Seattle Genetics Announces Interim Safety Analysis Supports Continuation Of Lintuzumab Phase IIb Clinical Trial
http://www.medicalnewstoday.com/articles/132714.php
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that an Independent Data Monitoring Committee (IDMC) has completed a pre-specified safety review of data from the ongoing phase IIb trial of lintuzumab (SGN-33) in combination with low-dose cytarabine chemotherapy for older patients with acute myeloid leukemia (AML).
ERYtech Pharma Announces The Results Of Its Phase II Clinical Trial
http://www.medicalnewstoday.com/articles/132700.php
ERYtech Pharma, the specialty pharmaceuticals company developing red cell-based medicinal products, announces the results of its phase II clinical trial. GRASPALL 2005-1 was presented orally on the 8th December 2008 at the 50th Annual Meeting of the American Society of Hematology in San Francisco (USA).
Data From Eight Clinical Trials Facilitated By The Multiple Myeloma Research Consortium (MMRC) Presented At The ASH Annual Meeting
http://www.medicalnewstoday.com/articles/132694.php
The Multiple Myeloma Research Consortium (MMRC) today announced that data from eight clinical trials in its portfolio as well as findings from the MMRC Multiple Myeloma Genomics Initiative were presented at the American Society of Hematology's (ASH) 50th Annual Meeting and Exposition held Dec.
Group In Lymphoma Research Chooses Revlimid For Study In Disease's Largest Patient Population
http://www.medicalnewstoday.com/articles/132674.php
Celgene International Sarl (Nasdaq: CELG) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA) today announced the initiation of an international randomized, double-blind, controlled Phase III study to evaluate the therapeutic potential of REVLIMID (lenalidomide) as a maintenance therapy for elderly, high-risk patients with diffuse large B-cell lymphoma (DLBCL) who have responded to standard first line Rituximab, Cyclophosphamide, Doxorubicin, Oncovin and Prednisolone (R-CHOP).
Prolonged Overall Survival For Patients With Acute Myeloid Leukemia Demonstrated By Data
http://www.medicalnewstoday.com/articles/132593.php
The Myelodysplastic Syndromes (MDS) Foundation have announced that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).
Promising Results From 2 Trials Highlighting Pomalidomide Presented At ASH
http://www.medicalnewstoday.com/articles/132590.php
Celgene International Sarl (Nasdaq: CELG) has announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis.
Data Presented At This Year's ASH Meeting Demonstrate Prolonged Overall Survival For Patients With Acute Myeloid Leukemia
http://www.medicalnewstoday.com/articles/132560.php
The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Cardiac Deaths Do Not Appear To Be Increased By Hormone Therapy For Prostate Cancer
http://www.medicalnewstoday.com/articles/132704.php
Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers.
Vitamin E Or Selenium Supplementation Not Associated With Reduced Risk Of Prostate Or Other Cancers
http://www.medicalnewstoday.com/articles/132532.php
Supplementation with either selenium or vitamin E does notappear to reduce the risk of prostate cancer or other cancers,according to a study released on early December 9, 2008 Online in <i>JAMA</i>.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment